OCI-AML-3  Xenografts

 

 

Rincon Bio performs OCI-AML-3 xenograft models to test efficacy of preclinical therapies.  Please see below for additional information or to request a quote. 

Leukemia/

Lymphoma

OCI-AML-3 was derived from a 57 year old man with acute myeloid leukemia in 1987. 

Notes

NPM1 mutation and DNMT3A R882C mutation

in vivo

Used in xenografts to test the efficacy of novel cancer therapeutics.  Tumors develop after being injected into the flank of immunocompromised mice. 

Request Quote

Receive a quote within one business day for a OCI-AML-3 xenograft

Rincon Bio Growth Curves

OCI-AML-3

oci-aml-3.png

Cell Line: OCI-AML3 

Mouse Strain: NOD.CB17-Prkdc*scidNCrHsd females (Envigo) 

Animals per Group: 10 

Positive Control: None 

Concentration: N/A 

Matrigel: Yes 

Dosing: N/A 

From implant to stratification: 14 days 

Cells Implanted per Animal: 10 million 

WHY WORK WITH

RINCON BIO?

DOMESTIC QUALITY at COMPETITIVE PRICES

 

When you work with Rincon Bio, rest assured that all cancer efficacy studies will be performed in the USA, at competitive prices

SPEED TO INITIATION
 

Most efficacy studies can be initiated within two business days.

PERSONAL TOUCH

 

We love our clients!  We are flexible and easy to work with.  And we take a personal interest in our clients' studies.